Current Report Filing (8-k)
July 06 2016 - 4:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 6, 2016
MEDIVATION, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-32836
|
|
13-3863260
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
525 Market Street, 36
th
Floor
San Francisco, California 94105
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (415) 543-3470
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01.
|
Regulation FD Disclosure.
|
On July 6, 2016, Medivation, Inc. (the Company)
will host an investor conference call and live audio webcast to provide a detailed review of its PARP inhibitor talazoparib. A copy of the slides that will accompany the investor presentation is attached hereto as Exhibit 99.1.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
|
|
|
99.1
|
|
Investor presentation titled Talazoparib (MDV3800): A Potentially Best-in-Class PARP Inhibitor
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
MEDIVATION, INC.
|
|
|
|
|
Dated: July 5, 2016
|
|
|
|
By:
|
|
/s/ Jennifer Jarrett
|
|
|
|
|
|
|
Jennifer Jarrett
Chief Financial
Officer
|
EXHIBIT INDEX
|
|
|
|
|
99.1
|
|
Investor presentation titled Talazoparib (MDV3800): A Potentially Best-in-Class PARP Inhibitor
|
Medivation, Inc. (MM) (NASDAQ:MDVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medivation, Inc. (MM) (NASDAQ:MDVN)
Historical Stock Chart
From Apr 2023 to Apr 2024